nach oben

Breast Cancer

Erschienen in:

03.11.2017 | Original Article

Candidate miRNAs in human breast cancer biomarkers: a systematic review

verfasst von: Masoumeh Adhami, Ali Akbar Haghdoost, Balal Sadeghi, Reza Malekpour Afshar

Erschienen in: Breast Cancer | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Breast cancer (BC) is the most prevalent cancer and the main cause of cancer deaths among females around the world. For early diagnosis of BC, there would be an immediate and essential requirement to search for sensitive biomarkers.

Methods

To identify candidate miRNA biomarkers for BC, we performed a general systematic review regarding the published miRNA profiling researches comparing miRNA expression level between BC and normal tissues. A miRNA ranking system was selected, which considered frequency of comparisons in direction and agreement of differential expression.

Results

We determined that two miRNAs (mir-21 and miR-210) were upregulated consistently and six miRNAs (miR-145, miR-139-5p, miR-195, miR-99a, miR-497 and miR-205) were downregulated consistently in at least three studies. MiR-21 as the most consistently reported miRNA was upregulated in six profiling studies.

Conclusions

Although these miRNAs require being validated and further investigated, they could be potential candidates for BC miRNA biomarkers and used for early prognosis or diagnosis.

Nur mit Berechtigung zugänglich

Torre Lindsey A, Siegel Rebecca L, Ferlay Jacques, Lortet-Tieulent Joannie, Jemal Ahmedin. Global Cancer Statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed

Smigal CJA, Ward E, Cokkinides V, Smith R, Howe HL, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006;56:168–83.CrossRefPubMed

Tryggvadottir LGM, Bray F, Klint A, Hakulinen T, Storm HH, et al. Trends in the survival of patients diagnosed with breast cancer in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49:624–31.CrossRefPubMed

Rosso SGA, Zanetti R, Bray F, Zakelj M, Zagar T, et al. Up-to-date estimates of breast cancer survival for the years 2000–2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer. 2010;46:3351–7.CrossRefPubMed

Holleczek BAV, Stegmaier C, Brenner H. Trends in breast cancer survival in Germany from 1976 to 2008—a period analysis by age and stage. Cancer Epidemiol. 2011;35:399–406.CrossRefPubMed

Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER cancer statistics review, 1975-2008. National Cancer Institute, Bethesda, MD. Based on November 2010 SEER data submission, posted to the SEER web site, 2011. http://seer.cancer.gov/csr/1975_2008/. Accessed 1 Aug 2017

Sankaranarayanan RSR, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010;11:165–73.CrossRefPubMed

Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer Epidemiol. 2007;43:1529–44.CrossRef

He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–31.CrossRefPubMed

10.

Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.CrossRefPubMed

11.

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMed

12.

Cummins JM, Velculescu VE. Implications of micro-RNA profiling for cancer diagnosis. Oncogene. 2006;25:6220–7.CrossRefPubMed

13.

Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25:6188–96.CrossRefPubMed

14.

Iorio MVCC. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4:143–59.CrossRefPubMedPubMedCentral

15.

Ma YZP, Yang J, Liu Z, Yang Z, et al. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer. 2012;130:2077–87.CrossRefPubMed

16.

Chan SKGO, Tai IT, Jones SJ. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomark Prev. 2008;17:543–52.CrossRef

17.

Griffith OLMA, Jones SJ, Wiseman SM. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol. 2006;24:5043–51.CrossRefPubMed

18.

Ji-Lin Wang YH, Xuan Kong, Zhen-Hua Wang, Hao-Yan Chen, Jie Xu, Jing-Yuan Fang. Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study. PLoS One. 2013;8:1–8.

19.

Sun J, Li M, Li Z, Xue J, Lan X, Zhang C, et al. Identification and profiling of conserved and novel microRNAs from Chinese Qinchuan bovine longissimus thoracis. BMC Genom. 2013;14:42.CrossRef

20.

Hu J, Xu J, Wu Y, Chen Q, Zheng W, Lu X, et al. Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. Tumour Biol. 2015;36:251–8.CrossRefPubMed

21.

Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–70.CrossRefPubMed

22.

Matamala N, Vargas MT, Gonzalez-Campora R, Minambres R, Arias JI, Menendez P, et al. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem. 2015;61:1098–106.CrossRefPubMed

23.

Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A, Yakhini Z. Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One. 2009;4:e8003.CrossRefPubMedPubMedCentral

24.

Pena-Chilet M, Martinez MT, Perez-Fidalgo JA, Peiro-Chova L, Oltra SS, Tormo E, et al. MicroRNA profile in very young women with breast cancer. BMC Cancer. 2014;14:529.CrossRefPubMedPubMedCentral

25.

Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007;67:11612–20.CrossRefPubMed

26.

Sun EH, Zhou Q, Liu KS, Wei W, Wang CM, Liu XF, et al. Screening miRNAs related to different subtypes of breast cancer with miRNAs microarray. Eur Rev Med Pharmacol Sci. 2014;18:2783–8.PubMed

27.

Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14:2348–60.CrossRefPubMedPubMedCentral

28.

Zhang K, Zhao S, Wang Q, Yang HS, Zhu J, Ma R. Identification of microRNAs in nipple discharge as potential diagnostic biomarkers for breast cancer. Ann Surg Oncol. 2015;22(Suppl 3):S536–44.CrossRefPubMed

29.

Zhang M, Liu D, Li W, Wu X, Gao C, Li X. Identification of featured biomarkers in breast cancer with microRNA microarray. Arch Gynecol Obstet. 2016;294:1047–53.CrossRefPubMed

30.

Bhattacharya A, Cui Y. SomamiR 2.0: a database of cancer somatic mutations altering microRNA–ceRNA interactions. Nucleic Acids Res. 2016;44(D1):D1005–10.CrossRefPubMed

31.

Meng X, Wang J, Yuan C, Li X, Zhou Y, Hofestadt R, et al. CancerNet: a database for decoding multilevel molecular interactions across diverse cancer types. Oncogenesis. 2015;4:e177.CrossRefPubMedPubMedCentral

32.

Thakur S, Grover RK, Gupta S, Yadav AK, Das BC. Identification of specific miRNA signature in paired sera and tissue samples of indian women with triple negative breast cancer. PLoS One. 2016;11:e0158946.CrossRefPubMedPubMedCentral

33.

Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, et al. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol. 2014;8:874–83.CrossRefPubMedPubMedCentral

34.

Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci. 2016;107:326–34.CrossRefPubMedPubMedCentral

35.

Alder HTC, Chen H, Jiang Y, Smalley KJ, et al. Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer. Carcinogenesis. 2012;33:1736–44.CrossRefPubMedPubMedCentral

36.

Iliopoulos DJS, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010;39:493–506.CrossRefPubMedPubMedCentral

37.

Han MWY, Liu M, Bi X, Bao J, et al. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1 a expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci. 2012;103:1058–64.CrossRefPubMed

38.

Fang HXJ, Zhang M, Zhao Z, Wan Y, Yao Y. miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am J Transl Res. 2017;9:953–61.PubMedPubMedCentral

39.

Tang YZX, Ji J, Chen L, Cao J, Luo J, Zhang S. High expression levels of miR-21 and miR-210 predict unfavorable survival in breast cancer: a systemic review and meta-analysis. Int J Biol Markers. 2015;30:e347–58.CrossRefPubMed

40.

Liu TY, HZ, Du SM, Li J, Wen XH. Expression of microRNA-210 in tissue and serum of renal carcinoma patients and its effect on renal carcinoma cell proliferation, apoptosis, and invasion. Genet Mol Res. 2016;15:15017746.PubMed

41.

Rothé FIM, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart M, Sotiriou C. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One. 2011;6:e20980.CrossRefPubMedPubMedCentral

42.

Liu DXH, Wang F, Chen C, Long J. MicroRNA-210 interacts with FBXO31 to regulate cancer proliferation cell cycle and migration in human breast cancer. Onco Targets Ther. 2016;23:5245–55.

43.

Bandrés ECE, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M, García-Foncillas J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;19(5):29–39.CrossRef

44.

Yanaihara NCN, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–98.CrossRefPubMed

45.

LE Szczyrba J, Wach S, Jung V, Unteregger G, Barth S, Grobholz R, Wieland W, Stöhr R, Hartmann A, Wullich B, Grässer F. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res. 2010;8:529–38.CrossRefPubMed

46.

Kano MSN, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, Matsubara H. miR-145, miR-133a and miR-133b: tumor suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer Cell. 2010;127:2804–14.CrossRef

47.

Zhao HKX, Xia X, Wo L, Gu X, Hu Y, Xie X, Chang H, Lou L, Shen X. miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. Am J Transl Res. 2016;8:3106–14.PubMedPubMedCentral

48.

Ding YZC, Zhang J, Zhang N, Li T, Fang J, Zhang Y, Zuo F, Tao Z, Tang S, Zhu W, Chen H, Sun X. miR-145 inhibits proliferation and migration of breast cancer cells by directly or indirectly regulating TGF-β1 expression. Int J Oncol. 2017;50:1701–10.CrossRefPubMed

49.

Enders KO, Ng RL, Vivian Shin Y, Hong Chuan Jin, Candy Leung PH, Edmond Ma SK, Roberta Pang, Daniel Chua, Kent-Man Chu, Law WL, Simon Law YK, Ronnie Poon TP, Ava Kwong. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One. 2013;8:e53141.CrossRef

50.

Chengcao Sun MS, Shujun Li, Xiaodong Sun, Cuili Yang, Yongyong Xi, Liang Wang, Feng Zhang, Yongyi Bi, Yunfeng Fu, Dejia Li. Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. Oncotarget. 2015;6:39756–92.PubMedPubMedCentral

51.

Yonemori MSN, Yoshino H, Matsushita R, Miyamoto K, Nakagawa M, Enokida H. Dual tumor-suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer. Cancer Sci. 2016;107:1233–42.CrossRefPubMedPubMedCentral

52.

Zhou QHL, Zhou YX, Li Y. MiR-195 suppresses cervical cancer migration and invasion through targeting Smad3. Int J Gynecol Cancer. 2016;26:817–24.CrossRefPubMed

53.

Zhang XXJ, Jiang T, Liu G, Wang D, Lu Y. MicroRNA-195 suppresses colorectal cancer cells proliferation via targeting FGF2 and regulating Wnt/β-catenin pathway. Am J Cancer Res. 2016;6:2631–40.PubMedPubMedCentral

54.

Srivastava AGH, Dimtchev A, Ramalinga M, Chijioke J, Marian C, Oermann EK, Uhm S, Kim JS, Chen LN, Li X, Berry DL, Kallakury BV, Chauhan SC, Collins SP, Suy S, Kumar D. MicroRNA profiling in prostate cancer–the diagnostic potential of urinary miR-205 and miR-214. PLoS One. 2013;8:e76994.CrossRefPubMedPubMedCentral

55.

Salajegheh AVH, Rahman Md A, Amin M, Smith RA, Lam AK. Modulatory role of miR-205 in angiogenesis and progression of thyroid cancer. J Mol Endocrinol. 2015;55:183–96.CrossRefPubMed

56.

Wang PMX, Huang Y, Lv Z, Liu J, Wang G, Meng W, Xue S, Zhang Q, Zhang P, Chen G. MicroRNA-497 inhibits thyroid cancer tumor growth and invasion by suppressing BDNF. Oncotarget. 2017;8:2825–34.PubMed

57.

Zhang YZZ, Li Z, Gong D, Zhan B, Man X, Kong C. MicroRNA-497 inhibits the proliferation, migration and invasion of human bladder transitional cell carcinoma cells by targeting E2F3. Oncol Rep. 2016;36:1293–300.CrossRefPubMed

58.

Feng Y KY, He Y, Liu J, Liang B, Yang P, Yu Z. MicroRNA-99a acts as a tumor suppressor and is down-regulated in bladder cancer. BMC Urol. 14 2014

59.

Yu SHZC, Dong FS, Zhang YM. miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway. J Cell Biochem. 2015;116:268–76.CrossRefPubMed

60.

Huang HGLX, Wu S, Jian B. MiR-99a inhibits cell proliferation and tumorigenesis through targeting mTOR in human anaplastic thyroid cancer. Asian Pac J Cancer Prev. 2015;16:4937–44.CrossRefPubMed

Titel: Candidate miRNAs in human breast cancer biomarkers: a systematic review
verfasst von: Masoumeh Adhami
Ali Akbar Haghdoost
Balal Sadeghi
Reza Malekpour Afshar
Publikationsdatum: 03.11.2017
Verlag: Springer Japan
Erschienen in: Breast Cancer / Ausgabe 2/2018
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-017-0814-8

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Candidate miRNAs in human breast cancer biomarkers: a systematic review

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Local anesthetic delivery via surgical drain provides improved pain control versus direct skin infiltration following axillary node dissection for breast cancer

Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation

Risk factors for complications among breast cancer patients treated with post-mastectomy radiotherapy and immediate tissue-expander/permanent implant reconstruction: a retrospective cohort study

UBAP2L silencing inhibits cell proliferation and G2/M phase transition in breast cancer

Correction to: A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women

Margin-free excision of small solid breast carcinomas using the Intact Breast Lesion Excision System®: is it feasible?

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie